Aphios Presents At Livingston Securities Trans-Atlantic Innovation Summit
October 17, 2012
Woburn, MA – Aphios Corporation will be presenting at the first Annual Livingston Securities Trans-Atlantic Innovation Summit being held on October 22, 2012, at the Alexandria Biotech Center in New York, NY. This event is being held in concert with the 5th Annual Livingston Securities Life Science Investor Conference.

Aphios is developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders such as Alzheimer's Disease. Aphios®, which means "virus-free" in Greek, was founded in 1993 as a Delaware C corporation. The company was founded by Dr. Trevor P. Castor, President and CEO, to develop enabling technology platforms around the delivery and viral safety of biologics such as human plasma and recombinant therapeutics, hence its "virus-free" name. Viral particles are given the "bends" and become inactive. This CFI pathogen inactivation technology is purely physical and does not result in the denaturation of surface proteins on the virion, making it an excellent candidate technology for inactivated viral vaccines, or the protein substrate which makes it an ideal pathogen inactivation technology for blood plasma, plasma proteins and recombinant biologics.

Aphios has reverse engineered CFI to establish three nanotechnology drug delivery platforms include: (1) CFN - phospholipid nanosomes for intravenous and/or topical administration of hydrophilic molecules including siRNA and hydrophobic anticancer drugs such as paclitaxel and camptothecin; (2) PNS - polymer nanospheres for oral/depot delivery of proteins such as insulin for diabetes, calcitonin for osteoporosis and controlled-release adjuvants of vaccine antigens for infectious diseases; and (3) PNP - protein nanoparticles for pulmonary delivery of proteins and polypeptides such as insulin for diabetes. We utilize these platforms in strategic collaborations with partners interested in improving drug delivery, establishing oral bio availability, or extending patent life. We also utilize these platforms for drug development such as our recent CFN nanoencapsulation of camptothecin, Camposomes™, that have demonstrated in in vivo preclinical studies a 30-fold improvement over a positive control Irinotecan in the treatment of human pancreatic cancer cell line in nude mice, and the PNS re-formulation of APH-0703 for oral administration in the treatment of Alzheimer's disease. We have also utilized PNS to demonstrate oral bioavailability of insulin in a mouse model of diabetes.

At its founding, the Company elected to spend about 10% of its research activities on investigating natural therapeutics. This interest has evolved to the realization that in order to solve the problems of cancer and aging, we have to look to nature, marine organisms and terrestrial plants that have learned how to control cell growth and cancerous mutation, often living for hundreds to thousands of years. To pursue these interests, we have developed an enabling CXF drug discovery platform that segues into an enabling CXP drug manufacturing platform. We have utilized these drug discovering and manufacturing platforms and when necessary, nanotechnologies, to develop our lead therapeutic products.

Our lead therapeutic products include: Zindol® an enhanced ginger product in Phase III for chemotherapy induced nausea and vomiting (CINV) with potential applications in post-operative nausea and vomiting (PONV), pregnancy related nausea and vomiting (PRNV) and motion sickness nausea and vomiting (MSNV); APH-0703, a potent protein kinase C (PKC) activator in Phase I/II as an intravenous therapeutic for ameliorating Alzheimer's Disease pathophysiology and cognitive impairment with neuroprotection, and being reformulated for oral administration by conventional and nanotechnology methods; APH-0812, a combination therapy consisting of PKC modulators with or without HDAC inhibitors in Phase I, designed to reactivate latent HIV reservoirs so that HIV can be eliminated by antiviral therapy and eradicated from the body; AMPI-109, a nontoxic Vitamin D3 derivative for hormone refractory prostate cancer (HRPCA) in formulation development for both intravenous and oral administration by conventional and nanotechnology methods, designed to have increased antiproliferative effects while reducing systemic toxicity through increased specificity.

Aphios® Corporation is a clinical stage biotechnology company developing green, enabling technology platforms for improved drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Based on these platforms, Aphios is developing enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and central nervous system disorders, such as Alzheimer's Disease. To learn more about Aphios, visit us at www.aphios.com.